New data suggests Abbott’s high sensitive troponin test may help doctors more accurately diagnose heart attacks in women
4 September 2013 | By Abbott
Abbott announced promising preliminary results from a study presented at the ESC Congress 2013...
List view / Grid view
News
Novartis showcases 39 abstracts highlighting robust respiratory portfolio at ERS 2013
4 September 2013 | By Novartis
Robust efficacy of once-daily Ultibro® Breezhaler® (QVA149) supported by a pooled analysis of the Phase III IGNITE clinical trial program further strengthens evidence for the Ultibro® LABA+LAMA combination for the treatment of COPD patients[1],[2],[3]...
Menomune® is the first quadrivalent meningococcal vaccine prequalified by the WHO
3 September 2013 | By Sanofi
Prequalification makes the vaccine eligible for purchase by United Nations Agencies...
Novartis receives EU approval for Ilaris® in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis
3 September 2013 | By Novartis
Ilaris® is the first interleukin-1 beta (IL-1 beta) inhibitor for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) and is the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection[1]...
Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim’s innovation promise in cardiovascular diseases
3 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announces new plans to expand body of evidence for Pradaxa®...
Amgen and Cytokinetics announce the first presentation of data from Phase 2 ATOMIC-AHF study of Omecamtiv Mecarbil
3 September 2013 | By Amgen
First trial to evaluate cardiac myosin activator in patients with acute heart failure presented at ESC Congress 2013...
Selcia and Cantab announce drug discovery collaboration
3 September 2013 | By O2PR LTD
Selcia Limited has entered into a drug discovery collaboration with Cantab Anti-Infectives...
Simultaneous applications submitted to FDA and EMA for siltuximab for the treatment of MCD, a rare blood disorder
3 September 2013 | By Johnson & Johnson
“We’re proud of our work on siltuximab. As a rare disease with a small patient population, MCD is an area of significant unmet need”
Subanalysis of Phase III ARISTOTLE trial of Eliquis® (apixaban) demonstrated consistent results versus warfarin in patients with NVAF with or without valvular heart disease
3 September 2013 | By Pfizer
Data show consistent results in reductions in stroke or systemic embolism, fewer major bleeding events, and reductions in all-cause death...
Novartis’ serelaxin (RLX030) improved symptoms and mortality across multiple subgroups of patients with acute heart failure[1],[2]
2 September 2013 | By Novartis
New analysis of RELAX-AHF published in the European Heart Journal and presented as a late breaker at the European Society of Cardiology congress[1],[2]...
GSK receives marketing authorisation from the European Commission for Tafinlar™ (dabrafenib)
2 September 2013 | By GlaxoSmithKline
GSK announced that the European Commission has granted marketing authorisation for Tafinlar™ (dabrafenib)...
Roche’s new timesaving formulation of Herceptin approved in Europe for the treatment of HER2-positive breast cancer
2 September 2013 | By Roche
Roche announced that a new injectable (subcutaneous) formulation of Herceptin (trastuzumab) has been approved by the European Commission...
Boehringer Ingelheim to present highly anticipated data from landmark TIOSPIR™ trial at ERS 2013
2 September 2013 | By Boehringer Ingelheim
Results from TIOSPIR™ will be presented for the first time at the Annual Congress of the European Respiratory Society...
ONGLYZA® (saxagliptin) demonstrates no increased risk for cardiovascular death, heart attack or stroke in SAVOR cardiovascular outcomes trial
2 September 2013 | By AstraZeneca
SAVOR provides information on cardiovascular safety for Onglyza in the wake of past questions about cardiovascular safety of type 2 diabetes treatments...
Daiichi Sankyo’s once-daily edoxaban shows comparable efficacy and superiority for the principal safety endpoint compared to warfarin in a Phase 3 study for the treatment of symptomatic VTE and prevention of its recurrence
1 September 2013 | By Daiichi Sankyo
Daiichi Sankyo announced results from the global phase 3 Hokusai-VTE study...
